
A panelist discusses how the POD1UM-303 randomized phase 3 trial demonstrated that adding retifanlimab (a PD-1 inhibitor) to carboplatin and paclitaxel significantly improved progression-free survival from 7.4 to 9.3 months with a 37% reduction in progression risk, showed strong trends toward overall survival improvement (23 to 29.2 months despite 45% crossover), increased complete response rates from 14% to 22% and doubled median duration of response from 7.2 to 14 months, establishing this combination as the new standard of care for advanced squamous cell anal carcinoma despite manageable immunotherapy-related side effects.






















